VivoSeq
Ophthalmology

Amblyopia

9

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Amblyopia is an early-stage landscape with 9 programs across 7 companies. The most active players are Hikma Pharmaceuticals LLC, AbbVie, Micelle BioPharma Inc. 3 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

11/100

Mech. Concentration

20/100

Completion Rate

79/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hikma Pharmaceuticals LLC

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 2M

Micelle BioPharma Inc

1 program

Phase 2F

Fresenius Kabi Oncology Ltd.

1 program

Phase 3Orion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

1 program

Phase 3M

Merz Pharmaceuticals GmbH

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

17

clinical trials

Completed11 · 65%
Not yet recruiting2 · 12%
Withdrawn2 · 12%
Recruiting1 · 6%
Terminated1 · 6%

Clinical Trials

Trial Activity

17 trials

Possible Beneficial Effects Of Combined Fluoxetine And Occlusion Therapy In Improving And Maintaining Vision In Amblyopia Using Optical Coherence Tomography Angiography (OCTA) And Visual Evoked Potential (VEP). The Aim Of The Study Is To Evaluate Possible Beneficial Effects For Different Age Groups.
Recruiting·MMinia University·N/A·NCT07417046·50 enrolled
Valproate for the Treatment of Residual Amblyopia
Not yet recruiting·—·Phase 1/2·NCT07226141·28 enrolled
Effectiveness and Safety of Augmented Reality-Based Amblyopia Training for Postoperative Congenital Cataract Patients: A Multicenter, Superiority, Randomized, Parallel-Controlled Trial Protocol
Not yet recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·Preclinical·NCT07693790·88 enrolled
Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
Completed·JJaeb Center for Health Research·Phase 3·NCT00000170·419 enrolled
Levodopa for the Treatment of Residual Amblyopia
Completed·JJaeb Center for Health Research·Phase 3·NCT01190813·139 enrolled
Treatment of Residual Amblyopia With Donepezil
Completed·—·Phase 1·NCT01584076·18 enrolled
Amblyopia (Lazy Eye) Treatment Study
Completed·National Eye Institute (NEI)·Phase 3·NCT00001864·20 enrolled
An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old
Completed·JJaeb Center for Health Research·Phase 3·NCT00094692·507 enrolled
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
Completed·JJaeb Center for Health Research·Phase 3·NCT00944710·73 enrolled
Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia
Completed·JJaeb Center for Health Research·Phase 2·NCT00789672·33 enrolled
Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old
Completed·JJaeb Center for Health Research·Phase 3·NCT00315302·240 enrolled
Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia
Completed·—·Phase 4·NCT03109314·20 enrolled
Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds
Completed·JJaeb Center for Health Research·Phase 3·NCT00315328·233 enrolled
Binocular Dig Rush Game Treatment for Amblyopia
Completed·JJaeb Center for Health Research·Preclinical·NCT02983552·320 enrolled
Combined Patching-Atropine for Residual Amblyopia
Terminated·JJaeb Center for Health Research·Phase 3·NCT00506675·55 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)